Literature DB >> 10908167

A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.

J Berwaerts1, J Verhelst, R Abs, B Appel, C Mahler.   

Abstract

We report the case of a 45-year-old male presenting with unilateral exophthalmos due to a large tumoral mass invading the skull base. Ophthalmologic examination did not show any visual field defects. Imaging techniques demonstrated extension of a huge tumor (approx. 8x8x8 cm) into the right orbit and nasopharynx. Endocrine work-up revealed grossly elevated serum prolactin (PRL) levels (26,466 microg/l, nl. < 12), pointing to a large, invasive macroprolactinoma. Stimulation tests indicated associated partial adrenal and growth hormone deficiencies. Planned surgery was abandoned, and the patient was instead treated with the long-acting dopamine agonist, cabergoline. Over a period of one year, serum PRL dropped to 131 microg/l, while the tumor mass shrank to less than 50% of its original volume (with 3.5 mg/week of cabergoline). The exophthalmos disappeared, and the patient did not develop rhinorrhea or any other side effects from treatment with cabergoline. The efficacy was maintained throughout the second year (ultimate serum PRL 74 microg/l, and final size less than 10% of the original). With reference to this case, we review other macroprolactinomas reported in the recent literature for associated exophthalmos, grossly elevated serum PRL levels (> or = 15,000 microg/l), and/or "giant" size (> or = 4 cm in maximum diameter). We highlight the use of dopamine agonists in the treatment of prolactinomas with such unusual characteristics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908167     DOI: 10.1007/BF03343743

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

1.  Giant basal prolactinoma extending into the nasal cavity.

Authors:  Y Iwai; A Hakuba; V K Khosla; M Nishikawa; J Katsuyama; Y Inoue; S Nishimura
Journal:  Surg Neurol       Date:  1992-04

2.  Neurological picture. A "giant" prolactinoma.

Authors:  U Reuter; S Mehraein; G Arnold; R Lehmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

3.  Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma.

Authors:  G Hildebrandt; J Zierski; P Christophis; A Laun; H Schatz; I Lancranjan; N Klug
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Treatment of macroprolactinoma with cabergoline: a study of 85 patients.

Authors:  C I Ferrari; R Abs; J S Bevan; G Brabant; E Ciccarelli; T Motta; M Mucci; M Muratori; L Musatti; G Verbessem; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  1997-04       Impact factor: 3.478

5.  Massive prolactinoma with galactorrhoea in a prepubertal boy.

Authors:  R J Ross; J M McEniery; A Grossman; I Doniach; G M Besser; M O Savage
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

6.  Giant pituitary adenomas.

Authors:  H W Pia; E Grote; G Hildebrandt
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

7.  Cerebrospinal fluid rhinorrhea: a complication of therapy for invasive prolactinomas.

Authors:  A M Landolt
Journal:  Neurosurgery       Date:  1982-09       Impact factor: 4.654

8.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

9.  Giant invasive prolactinomas.

Authors:  F Y Murphy; D L Vesely; R M Jordan; S Flanigan; P O Kohler
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

10.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

View more
  7 in total

1.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  How to investigate and treat: headache and hyperprolactinemia.

Authors:  Gennaro Bussone; Susanna Usai; Franca Moschiano
Journal:  Curr Pain Headache Rep       Date:  2012-08

Review 3.  Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.

Authors:  C Campana; F Nista; L Castelletti; M Caputo; E Lavezzi; P Marzullo; A Ferrero; G Gaggero; F R Canevari; D C Rossi; G Zona; A Lania; D Ferone; F Gatto
Journal:  J Endocrinol Invest       Date:  2022-02-11       Impact factor: 5.467

Review 4.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

5.  Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population.

Authors:  Farida Chentli; Said Azzoug; Katia Daffeur; Lina Akkache; Hadjer Zellagui; Meriem Haddad; Nadia Kalafate
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

6.  Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.

Authors:  Ze Rui Wu; Yong Zhang; Lin Cai; Shao Jian Lin; Zhi Peng Su; Yong Xu Wei; Han Bing Shang; Wen Lei Yang; Wei Guo Zhao; Zhe Bao Wu
Journal:  Int J Endocrinol       Date:  2016-11-23       Impact factor: 3.257

7.  Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma.

Authors:  Shadin Alkatari; Naji Aljohani
Journal:  Clin Med Insights Case Rep       Date:  2012-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.